What Can We Learn from the Groundbreaking Research of Dennis L. We weren’t able to create a summary for you. Refresh your page to try again. Oct 19, 2023 · In this interview, Dr. Slamon talks about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research . Oct 19, 2023 · In this interview, Dr. Slamon talks about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research . Clinical researchersDennisSlamon, MD, PhD, and Brian Druker, MD, were recently honored with the 2019 Sjöberg Prize for their ground-breaking contributions toward targeted therapy for patients with breast cancer and chronic myeloid leukemia, respectively. DennisSlamon: The MONALEESA-3 trial’s designed to look at a CDK4/6 inhibitor, in this case ribociclib, in combination with hormonal therapy, a very effective hormonal therapy, fulvestrant, versus fulvestrant plus a placebo, to ask a couple of questions. DennisSlamon, a UCLA scientist whose research led to the development of the blockbuster breast cancer drug Herceptin, will share in a $1 million prize from Sweden for outstanding cancer research, the university announced Feb. 5 Istituto Nazionale Tumori IRCCS "Fondazione G. 6 Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. 7 Masaryk Memorial Cancer Institute, Brno, Czech Republic. Traditional research is human-led, deep-research is AI-assisted, and vibe-research is AI-led with human oversight. It doesn’t cut people out, it shifts their role so that researchers can focus on the big questions that drive discoveries.Towards AI Scientists that learnfromthe lab.
